Wh Wilson Tang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6384285/publications.pdf

Version: 2024-02-01

729 papers	69,186 citations	1530 106 h-index	890 242 g-index
872 all docs	872 docs citations	872 times ranked	57990 citing authors

#	Article	IF	Citations
1	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	1.2	7,017
2	Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 2011, 472, 57-63.	13.7	4,238
3	Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine, 2013, 19, 576-585.	15.2	3,355
4	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
5	Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. New England Journal of Medicine, 2013, 368, 1575-1584.	13.9	2,537
6	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
7	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	9.4	1,685
8	Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell, 2016, 165, 111-124.	13.5	1,358
9	Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. Journal of the American College of Cardiology, 2009, 53, 589-596.	1.2	1,313
10	HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, e1-e2.	0.7	1,086
11	Gut Microbiota in Cardiovascular Health and Disease. Circulation Research, 2017, 120, 1183-1196.	2.0	1,079
12	Gut Microbiota-Dependent Trimethylamine N -Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease. Circulation Research, 2015, 116, 448-455.	2.0	898
13	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation, 2019, 139, e840-e878.	1.6	619
14	The use of diuretics in heart failure with congestion â€" a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	2.9	605
15	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	13.7	581
16	Prognostic Value of Elevated Levels of Intestinal Microbe-Generated Metabolite Trimethylamine-N-Oxide in Patients With Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1908-1914.	1.2	533
17	The contributory role of gut microbiota in cardiovascular disease. Journal of Clinical Investigation, 2014, 124, 4204-4211.	3.9	519
18	Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. European Heart Journal, 2014, 35, 904-910.	1.0	463

#	ARTICLE	IF	CITATIONS
19	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2015, 373, 2314-2324.	13.9	453
20	Dietary metabolism, the gut microbiome, and heart failure. Nature Reviews Cardiology, 2019, 16, 137-154.	6.1	449
21	Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program. Journal of the American College of Cardiology, 2009, 53, 765-773.	1.2	424
22	Î³-Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAO. Cell Metabolism, 2014, 20, 799-812.	7.2	416
23	Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. American Journal of Medicine, 2008, 121, 748-757.	0.6	411
24	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. JAMA - Journal of the American Medical Association, 2013, 310, 2533.	3.8	410
25	New gene functions in megakaryopoiesis and platelet formation. Nature, 2011, 480, 201-208.	13.7	401
26	A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. Cell, 2020, 180, 862-877.e22.	13.5	397
27	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Journal of the National Cancer Institute, 2010, 102, 596-604.	3.0	381
28	Elevated Intra-Abdominal Pressure in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2008, 51, 300-306.	1.2	374
29	Cardiac troponins in renal insufficiency. Journal of the American College of Cardiology, 2002, 40, 2065-2071.	1.2	353
30	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. JAMA - Journal of the American Medical Association, 2017, 317, 1958.	3.8	329
31	Abdominal Contributions to Cardiorenal Dysfunction in Congestive Heart Failure. Journal of the American College of Cardiology, 2013, 62, 485-495.	1.2	322
32	Seventy-five genetic loci influencing the human red blood cell. Nature, 2012, 492, 369-375.	13.7	320
33	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2011, 4, 180-187.	1.6	319
34	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. European Heart Journal, 2017, 38, ehw582.	1.0	317
35	An abundant dysfunctional apolipoprotein A1 in human atheroma. Nature Medicine, 2014, 20, 193-203.	15.2	316
36	Intestinal Microbiota in Cardiovascular Health and Disease. Journal of the American College of Cardiology, 2019, 73, 2089-2105.	1.2	301

#	Article	IF	Citations
37	Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. European Heart Journal, 2019, 40, 583-594.	1.0	297
38	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics, 2015, 47, 1282-1293.	9.4	294
39	Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARe Project. PLoS Genetics, 2011, 7, e1001300.	1.5	290
40	2013 ACCF/AHA Guideline for the Management ofÂHeartÂFailure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	1.2	276
41	Intestinal Microbiota-Dependent Phosphatidylcholine Metabolites, Diastolic Dysfunction, and Adverse Clinical Outcomes in Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2015, 21, 91-96.	0.7	271
42	Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1696-1705.	1.1	269
43	Choline Diet and Its Gut Microbeâ€“Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overloadâ€“Induced Heart Failure. Circulation: Heart Failure, 2016, 9, e002314.	1.6	265
44	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. Clinical Chemistry, 2007, 53, 2086-2096.	1.5	239
45	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. Circulation, 2015, 131, 1763-1771.	1.6	239
46	Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation, 2018, 137, 2016-2028.	1.6	239
47	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Circulation, 2007, 116, e99-109.	1.6	234
48	Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure. Journal of the American College of Cardiology, 2008, 52, 750-754.	1.2	231
49	Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. Journal of Clinical Investigation, 2013, 123, 3815-3828.	3.9	226
50	Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2009, 2, 1369-1377.	2.3	221
51	RNA-Seq identifies novel myocardial gene expression signatures of heart failure. Genomics, 2015, 105, 83-89.	1.3	220
52	Deep learning for cardiovascular medicine: a practical primer. European Heart Journal, 2019, 40, 2058-2073.	1.0	218
53	Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Worsening Renal Function in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2010, 16, 49-54.	0.7	217
54	Ventricular Geometry, Strain, and Rotational Mechanics in Pulmonary Hypertension. Circulation, 2010, 121, 259-266.	1.6	216

#	Article	IF	Citations
55	l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. Journal of Clinical Investigation, 2018, 129, 373-387.	3.9	216
56	Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure. Circulation, 2003, 108, 2964-2966.	1.6	213
57	Evaluation of kidney function throughout the heart failure trajectoryÂâ€“Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 584-603.	2.9	213
58	Role of the CHADS2Score in the Evaluation of Thromboembolic Risk in Patients With Atrial Fibrillation Undergoing Transesophageal Echocardiography Before Pulmonary Vein Isolation. Journal of the American College of Cardiology, 2009, 54, 2032-2039.	1.2	210
59	Loop Diuretic Efficiency. Circulation: Heart Failure, 2014, 7, 261-270.	1.6	209
60	Tenosynovial and Cardiac Amyloidosis inÂPatients Undergoing CarpalÂTunnelÂRelease. Journal of the American College of Cardiology, 2018, 72, 2040-2050.	1.2	209
61	Gut Microbe-Generated Trimethylamine N -Oxide From Dietary Choline Is Prothrombotic in Subjects. Circulation, 2017, 135, 1671-1673.	1.6	206
62	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	3.0	199
63	Intestinal Microbiotaâ€Generated Metabolite Trimethylamineâ€•Nâ€ Oxide and 5â€Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGEâ€Like Patient Cohort. Journal of the American Heart Association, 2016, 5, .	1.6	198
64	The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Reports, 2017, 19, 2451-2461.	2.9	194
65	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	3.8	187
66	Plasma Trimethylamine N -Oxide, a Gut Microbeâ€“Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic Burden. Journal of the American College of Cardiology, 2016, 67, 2620-2628.	1.2	186
67	Sodium Nitroprusside for Advanced Low-Output Heart Failure. Journal of the American College of Cardiology, 2008, 52, 200-207.	1.2	184
68	Machine learning prediction in cardiovascular diseases: a meta-analysis. Scientific Reports, 2020, 10, 16057.	1.6	182
69	Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus. Clinical Chemistry, 2017, 63, 297-306.	1.5	181
70	Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical Outcomes. Journal of Cardiac Failure, 2009, 15, 565-571.	0.7	180
71	Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. Journal of Cardiac Failure, 2015, 21, 973-980.	0.7	179
72	Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk. Journal of the American College of Cardiology, 2009, 53, 2061-2067.	1.2	174

#	Article	IF	Citations
73	Usefulness of Plasma Galectin-3 Levels in Systolic Heart Failure to Predict Renal Insufficiency and Survival. American Journal of Cardiology, 2011, 108, 385-390.	0.7	169
74	Phenomapping of patients with heart failure with preserved ejection fraction using machine learningâ€based unsupervised cluster analysis. European Journal of Heart Failure, 2020, 22, 148-158.	2.9	169
75	Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 49, 2364-2370.	1.2	163
76	Systematic Error Removal Using Random Forest for Normalizing Large-Scale Untargeted Lipidomics Data. Analytical Chemistry, 2019, 91, 3590-3596.	3.2	163
77	Plasma Myeloperoxidase Levels in Patients With Chronic Heart Failure. American Journal of Cardiology, 2006, 98, 796-799.	0.7	162
78	Prompt Reduction in Intra-Abdominal Pressure Following Large-Volume Mechanical Fluid Removal Improves Renal Insufficiency in Refractory Decompensated Heart Failure. Journal of Cardiac Failure, 2008, 14, 508-514.	0.7	162
79	Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. Journal of the American College of Cardiology, 2003, 41, 1394-1398.	1.2	157
80	Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2803-2812.	1.1	153
81	Timing of Hemoconcentration During Treatment of Acute Decompensated Heart Failure and Subsequent Survival. Journal of the American College of Cardiology, 2013, 62, 516-524.	1.2	148
82	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. Journal of Cardiac Failure, 2016, 22, 753-760.	0.7	141
83	Gut microbiome and its role in cardiovascular diseases. Current Opinion in Cardiology, 2017, 32, 761-766.	0.8	139
84	Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2008, 51, 569-576.	1.2	133
85	Trimethylamine N â€Oxide and Mortality Risk in Patients With Peripheral Artery Disease. Journal of the American Heart Association, 2016, 5, .	1.6	133
86	Plasma B-Type Natriuretic Peptide Levels Predict Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. Circulation, 2004, 110, 124-127.	1.6	131
87	Incremental Prognostic Value of Assessing Left Ventricular Myocardial Mechanics in Patients With Chronic Systolic Heart Failure. Journal of the American College of Cardiology, 2012, 60, 2074-2081.	1.2	131
88	Right Atrial Volume Index in Chronic Systolic Heart Failure and Prognosis. JACC: Cardiovascular Imaging, 2009, 2, 527-534.	2.3	126
89	Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. European Heart Journal, 2017, 38, 1872-1882.	1.0	126
90	A Genome-Wide Association Study for Coronary Artery Disease Identifies a Novel Susceptibility Locus in the Major Histocompatibility Complex. Circulation: Cardiovascular Genetics, 2012, 5, 217-225.	5.1	125

#	Article	IF	Citations
91	The kidney in congestive heart failure: â€˜are natriuresis, sodium, and diuretics really the good, the bad and the ugly?â€™. European Journal of Heart Failure, 2014, 16, 133-142.	2.9	125
92	The Pathophysiological Role of Interstitial Sodium in Heart Failure. Journal of the American College of Cardiology, 2015, 65, 378-388.	1.2	125
93	Hyponatremia in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2015, 65, 480-492.	1.2	124
94	Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2015, 66, 659-666.	1.2	123
95	Prognostic Role of Pulmonary Arterial Capacitance in Advanced Heart Failure. Circulation: Heart Failure, 2012, 5, 778-785.	1.6	122
96	Protein Carbamylation Predicts Mortality in ESRD. Journal of the American Society of Nephrology: JASN, 2013, 24, 853-861.	3.0	122
97	Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. JCI Insight, 2018, 3, .	2.3	122
98	Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential. Circulation Research, 2018, 123, 1164-1176.	2.0	122
99	Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated With Poor Long-Term Outcomes in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2014, 20, 392-399.	0.7	120
100	Comparative Genome-Wide Association Studies in Mice and Humans for Trimethylamine N -Oxide, a Proatherogenic Metabolite of Choline and <scp>l</scp> -Carnitine. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1307-1313.	1.1	119
101	Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood, 2011, 117, 3485-3493.	0.6	118
102	Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. European Heart Journal, 2013, 34, 2472-2480.	1.0	114
103	The Gut Microbiome and Its Role in Cardiovascular Diseases. Circulation, 2017, 135, 1008-1010.	1.6	113
104	Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. European Heart Journal, 2021, 42, 919-933.	1.0	113
105	PVDOMICS. Circulation Research, 2017, 121, 1136-1139.	2.0	113
106	Usefulness of Neutrophil-to-Lymphocyte Ratio in Risk Stratification of Patients With Advanced Heart Failure. American Journal of Cardiology, 2015, 115, 57-61.	0.7	111
107	Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1383-1391.	1.1	110
108	Diuretic response in acute heart failureâ€”an analysis from ASCEND-HF. American Heart Journal, 2015, 170, 313-321.e4.	1.2	110

#	Article	IF	Citations
109	Cardiorenal syndrome in decompensated heart failure. Heart, 2010, 96, 255-260.	1.2	109
110	Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation: Heart Failure, 2016, 9, e002370.	1.6	109
111	Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. American Heart Journal, 2012, 163, 156-163.	1.2	108
112	Terminology and definition of changes renal function in heart failure. European Heart Journal, 2014, 35, 3413-3416.	1.0	108
113	Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. Nature Communications, 2016, 7, 10558.	5.8	108
114	Insulin resistance in idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 78-81.	1.2	107
115	Microbiome, trimethylamine N-oxide, and cardiometabolic disease. Translational Research, 2017, 179, 108-115.	2.2	105
116	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	1.9	104
117	Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. European Heart Journal, 2008, 29, 2506-2513.	1.0	103
118	Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. Journal of Nuclear Cardiology, 2014, 21, 271-283.	1.4	103
119	Changes in Intrathoracic Impedance are Associated With Subsequent Risk of Hospitalizations for Acute Decompensated Heart Failure: Clinical Utility of Implanted Device Monitoring Without a Patient Alert. Journal of Cardiac Failure, 2009, 15, 475-481.	0.7	102
120	Measuring impedance in congestive heart failure: Current options and clinical applications. American Heart Journal, 2009, 157, 402-411.	1.2	102
121	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology, 2014, 63, 853-871.	1.2	102
122	Hypochloremia and Diuretic Resistance in Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	102
123	Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1239-1255.	1.1	102
124	Troponin I in acute decompensated heart failure: insights from the ASCENDâ€HF study. European Journal of Heart Failure, 2012, 14, 1257-1264.	2.9	101
125	Increased Need for Right Ventricular Support in Patients With Chemotherapy-Induced Cardiomyopathy Undergoing Mechanical Circulatory Support. Journal of the American College of Cardiology, 2014, 63, 240-248.	1.2	99
126	Function and Distribution of Apolipoprotein A1 in the Artery Wall Are Markedly Distinct From Those in Plasma. Circulation, 2013, 128, 1644-1655.	1.6	98

#	Article	IF	Citations
127	Reduced Cardiac Index Is Not theÂDominant Driver of RenalÂDysfunctionÂinÂHeart Failure. Journal of the American College of Cardiology, 2016, 67, 2199-2208.	1.2	98
128	Intrarenal Flow Alterations During Transition From Euvolemia to Intravascular Volume Expansion in Heart Failure Patients. JACC: Heart Failure, 2017, 5, 672-681.	1.9	98
129	Hemodialysisâ€induced cardiovascular disease. Seminars in Dialysis, 2018, 31, 258-267.	0.7	97
130	Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. Journal of Heart and Lung Transplantation, 2012, 31, 282-287.	0.3	96
131	Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure. Current Heart Failure Reports, 2014, 11, 58-63.	1.3	95
132	Protein carbamylation and cardiovascular disease. Kidney International, 2015, 88, 474-478.	2.6	94
133	Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. European Journal of Heart Failure, 2016, 18, 660-668.	2.9	94
134	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Journal of the American Heart Association, 2020, 9, e014708.	1.6	94
135	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. Journal of Cardiac Failure, 2012, 18, 94-106.	0.7	93
136	Differential Response to Cardiac Resynchronization Therapy and Clinical Outcomes According to QRS Morphology and QRS Duration. Journal of the American College of Cardiology, 2012, 60, 592-598.	1.2	93
137	Fasting 2-Deoxy-2-[¹⁸F]fluoro-<scp>d</scp>-glucose Positron Emission Tomography to Detect Metabolic Changes in Pulmonary Arterial Hypertension Hearts over 1 Year. Annals of the American Thoracic Society, 2013, 10, 1-9.	1.5	93
138	Right Ventricular Global Longitudinal Strain Provides Prognostic Value Incremental to Left Ventricular Ejection Fraction in Patients with Heart Failure. Journal of the American Society of Echocardiography, 2014, 27, 726-732.	1.2	93
139	Right Ventricular Response to Intensive Medical Therapy in Advanced Decompensated Heart Failure. Circulation: Heart Failure, 2010, 3, 340-346.	1.6	92
140	Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. European Journal of Heart Failure, 2013, 15, 433-440.	2.9	89
141	Improved Prediction of Cardiovascular Disease Based on a Panel of Single Nucleotide Polymorphisms Identified Through Genome-Wide Association Studies. Circulation: Cardiovascular Genetics, 2010, 3, 468-474.	5.1	88
142	Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated HeartÂFailure Treatment. American Journal of Medicine, 2015, 128, 776-783.e4.	0.6	88
143	Extracorporeal Ultrafiltration for FluidÂOverload in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2428-2445.	1.2	88
144	Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. Journal of the American College of Cardiology, 2017, 70, 152-162.	1.2	87

#	Article	IF	Citations
145	Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. Clinical Chemistry, 2011, 57, 33-39.	1.5	86
146	Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. Journal of the American College of Cardiology, 2002, 39, 70-78.	1.2	85
147	CD36 and Na/K-ATPase-Î±1 Form a Proinflammatory Signaling Loop in Kidney. Hypertension, 2013, 61, 216-224.	1.3	84
148	Site-specific Nitration of Apolipoprotein A-I at Tyrosine 166 Is Both Abundant within Human Atherosclerotic Plaque and Dysfunctional. Journal of Biological Chemistry, 2014, 289, 10276-10292.	1.6	84
149	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
150	Impact of Systemic Venous Congestion in Heart Failure. Current Heart Failure Reports, 2011, 8, 233-241.	1.3	82
151	Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. European Journal of Heart Failure, 2017, 19, 1014-1022.	2.9	80
152	Intrarenal Venous Flow. JACC: Heart Failure, 2016, 4, 683-686.	1.9	79
153	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. European Heart Journal, 2019, 40, 2700-2709.	1.0	79
154	Long-Term Reverse Remodeling With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2010, 55, 1788-1795.	1.2	78
155	Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart, 2012, 98, 1778-1786.	1.2	77
156	Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Journal of Lipid Research, 2010, 51, 3055-3061.	2.0	76
157	Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. European Journal of Heart Failure, 2012, 14, 597-604.	2.9	76
158	Cardiorenal Outcomes After Slow Continuous Ultrafiltration Therapy in Refractory Patients With Advanced Decompensated Heart Failure. Journal of the American College of Cardiology, 2012, 60, 1906-1912.	1.2	76
159	Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure. Journal of the American Society of Nephrology: JASN, 2017, 28, 3414-3424.	3.0	75
160	Outcomes of Patients With Stable Heart Failure Undergoing Elective Noncardiac Surgery. Mayo Clinic Proceedings, 2008, 83, 280-288.	1.4	74
161	Epigenetics in Cardiac Hypertrophy andÂHeartÂFailure. JACC Basic To Translational Science, 2019, 4, 976-993.	1.9	74
162	Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 766-772.	1.6	71

#	Article	IF	Citations
163	Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiologica, 2015, 70, 265-273.	0.3	71
164	Impact of Individual Traits, Saturated Fat, and Protein Source on the Gut Microbiome. MBio, 2018, 9, .	1.8	70
165	Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. European Journal of Heart Failure, 2019, 21, 1415-1422.	2.9	70
166	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	1.6	70
167	Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. JCI Insight, 2017, 2, .	2.3	69
168	Single Exhaled Breath Metabolomic Analysis Identifies Unique Breathprint in Patients With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1463-1464.	1.2	68
169	Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart, 2013, 99, 681-689.	1.2	68
170	Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events. Circulation: Heart Failure, 2012, 5, 602-609.	1.6	67
171	Novel Urinary Biomarkers in Detecting Acute Kidney Injury, Persistent Renal Impairment, and All-Cause Mortality Following Decongestive Therapy in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2013, 19, 621-628.	0.7	67
172	Exploring the Microbiome in Heart Failure. Current Heart Failure Reports, 2016, 13, 103-109.	1.3	67
173	Reverse Remodeling and Prognosis Following Kidney Transplantation in Contemporary Patients With Cardiac Dysfunction. Journal of the American College of Cardiology, 2015, 66, 1779-1787.	1.2	66
174	Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications. Current Heart Failure Reports, 2017, 14, 117-126.	1.3	66
175	Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure. Journal of the American College of Cardiology, 2009, 53, 600-607.	1.2	65
176	Diminished Antioxidant Activity of High-Density Lipoproteinâ€“Associated Proteins in Systolic Heart Failure. Circulation: Heart Failure, 2011, 4, 59-64.	1.6	65
177	Relation of Systemic and Urinary Neutrophil Gelatinase-Associated Lipocalin Levels to Different Aspects of Impaired Renal Function in Patients With Acute Decompensated Heart Failure. American Journal of Cardiology, 2012, 110, 1329-1335.	0.7	65
178	Early and late effects of cardiac resynchronization therapy on forceâ€“frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm, 2008, 5, 52-59.	0.3	64
179	Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. International Journal of Cardiology, 2017, 232, 12-23.	0.8	64
180	Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. JACC: Heart Failure, 2017, 5, 823-832.	1.9	63

#	Article	IF	Citations
181	Gut microbiota in cardiovascular disease and heart failure. Clinical Science, 2018, 132, 85-91.	1.8	63
182	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	1.0	63
183	Translating Metabolomics to Cardiovascular Biomarkers. Progress in Cardiovascular Diseases, 2012, 55, 70-76.	1.6	62
184	Prognostic Significance of Left Atrial Appendage â€œSludgeâ€•in Patients with Atrial Fibrillation: A New Transesophageal Echocardiographic Thromboembolic Risk Factor. Journal of the American Society of Echocardiography, 2014, 27, 1176-1183.	1.2	62
185	Gut Microbiota and Atherosclerosis. Current Atherosclerosis Reports, 2017, 19, 39.	2.0	62
186	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Current Hypertension Reports, 2018, 20, 75.	1.5	62
187	Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism: Clinical and Experimental, 2021, 116, 154457.	1.5	62
188	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Clinical Biochemistry, 2008, 41, 210-221.	0.8	61
189	Diminished Antioxidant Activity of High-Density Lipoprotein-Associated Proteins in Chronic Kidney Disease. Journal of the American Heart Association, 2013, 2, e000104-e000104.	1.6	61
190	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, e002453.	1.6	61
191	Nonlethal Inhibition of Gut Microbial Trimethylamine Nâ€oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure. Journal of the American Heart Association, 2020, 9, e016223.	1.6	61
192	Usefulness of Myeloperoxidase Levels in Healthy Elderly Subjects to Predict Risk of Developing Heart Failure. American Journal of Cardiology, 2009, 103, 1269-1274.	0.7	60
193	The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapyâ€”the IRON-CRT trial. European Heart Journal, 2021, 42, 4905-4914.	1.0	60
194	Encephalitis Owing to Human Herpesvirus-6 after Cardiac Transplant. American Journal of Transplantation, 2004, 4, 1200-1203.	2.6	59
195	Myeloperoxidase Mediates Postischemic Arrhythmogenic Ventricular Remodeling. Circulation Research, 2017, 121, 56-70.	2.0	59
196	Real World Use of Hypertonic Saline in Refractory Acute Decompensated HeartÂFailure. JACC: Heart Failure, 2020, 8, 199-208.	1.9	59
197	Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden. Journal of the American College of Cardiology, 2013, 61, 957-970.	1.2	58
198	Response to cardiac resynchronization therapy in elderly patients (â‰¥70 years) and octogenarians. European Journal of Heart Failure, 2013, 15, 203-210.	2.9	58

#	Article	IF	Citations
199	Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. Journal of Molecular and Cellular Cardiology, 2021, 152, 105-117.	0.9	58
200	Design and Performance of a Multisensor Heart Failure Monitoring Algorithm: Results From the Multisensor Monitoring in Congestive Heart Failure (MUSIC) Study. Journal of Cardiac Failure, 2012, 18, 289-295.	0.7	57
201	Dexamethasone, light anaesthesia, and tight glucose control (DeLiT) randomized controlled trial. British Journal of Anaesthesia, 2013, 111, 209-221.	1.5	57
202	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2014, 20, 319-326.	0.7	57
203	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal, 2015, 170, 290-297.e1.	1.2	57
204	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
205	Usefulness of C-Reactive Protein and Left Ventricular Diastolic Performance for Prognosis in Patients With Left Ventricular Systolic Heart Failure. American Journal of Cardiology, 2008, 101, 370-373.	0.7	56
206	Impact of Myocardial Function on Cystatin C Measurements in Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2008, 14, 394-399.	0.7	56
207	Pulmonary Hypertension Associated With Advanced Systolic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1150-1158.	1.2	56
208	A Randomized Controlled Pilot Study of Outcomes of Strict Allowance of Fluid Therapy in Hyponatremic Heart Failure (SALT-HF). Journal of Cardiac Failure, 2013, 19, 1-9.	0.7	56
209	A Test in Context. Journal of the American College of Cardiology, 2016, 67, 330-337.	1.2	56
210	Renal Dysfunction Is a Stronger Determinant of Systemic Neutrophil Gelatinaseâ€“Associated Lipocalin Levels Than Myocardial Dysfunction in Systolic Heart Failure. Journal of Cardiac Failure, 2011, 17, 472-478.	0.7	55
211	Importance of Adjunctive Heart Failure Optimization Immediately After Implantation to Improve Long-Term Outcomes With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2011, 108, 409-415.	0.7	55
212	Mast Cell Number, Phenotype, and Function in Human Pulmonary Arterial Hypertension. Pulmonary Circulation, 2012, 2, 220-228.	0.8	55
213	Clinical and Genetic Association of Serum Ceruloplasmin With Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 516-522.	1.1	54
214	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 594-600.	0.9	53
215	Progressive Rise in Red Cell Distribution Width Is Associated With Disease Progression in Ambulatory Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2012, 18, 146-152.	0.7	53
216	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. Journal of Cardiac Failure, 2013, 19, 371-389.	0.7	53

#	Article	IF	Citations
217	Report of the National Heart, Lung, and Blood Institute Working Group on the Role of Microbiota in Blood Pressure Regulation. Hypertension, 2017, 70, 479-485.	1.3	53
218	Impact of Mitral Regurgitation on Reverse Remodeling and Outcome in Patients Undergoing Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2012, 5, 21-26.	1.3	52
219	Ambient Air Pollution Is Associated With the Severity of Coronary Atherosclerosis and Incident Myocardial Infarction in Patients Undergoing Elective Cardiac Evaluation. Journal of the American Heart Association, 2016, 5, .	1.6	51
220	Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a perâ€protocol analysis of CARRESSâ€HF. European Journal of Heart Failure, 2018, 20, 1148-1156.	2.9	51
221	Natriuretic Response Is Highly Variable and Associated With 6-Month Survival. JACC: Heart Failure, 2019, 7, 383-391.	1.9	51
222	Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis. Circulation Research, 2020, 127, 827-846.	2.0	51
223	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2012, 18, 265-281.	0.7	50
224	Extracorporeal Ultrafiltration vs Conventional Diuretic Therapy in Advanced Decompensated Heart Failure. Congestive Heart Failure, 2012, 18, 54-63.	2.0	50
225	Global myocardial oedema in advanced decompensated heart failure. European Heart Journal Cardiovascular Imaging, 2017, 18, 787-794.	0.5	50
226	Patterns of Î²-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. American Heart Journal, 2004, 147, 79-83.	1.2	49
227	Consensus conference on heart-kidney transplantation. American Journal of Transplantation, 2021, 21, 2459-2467.	2.6	49
228	miRNA-548c: A specific signature in circulating PBMCs from dilated cardiomyopathy patients. Journal of Molecular and Cellular Cardiology, 2013, 62, 131-141.	0.9	48
229	Prognosis of Morbid Obesity Patients With Advanced Heart Failure. Congestive Heart Failure, 2013, 19, 160-164.	2.0	48
230	Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure. Circulation: Heart Failure, 2015, 8, 1068-1076.	1.6	48
231	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2016, 22, 26-32.	0.7	48
232	Increased mortality with elevated plasma endothelinâ€1 in acute heart failure: an ASCENDâ€HF biomarker substudy. European Journal of Heart Failure, 2016, 18, 290-297.	2.9	47
233	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	0.7	47
234	Cardiotonic Modulation in Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1073-1074.	1.2	46

#	Article	IF	Citations
235	Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study. Circulation: Heart Failure, 2013, 6, 936-943.	1.6	46
236	A Combined-Biomarker Approach to Clinical Phenotyping Renal Dysfunction in Heart Failure. Journal of Cardiac Failure, 2014, 20, 912-919.	0.7	46
237	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
238	Predictors of Response to Cardiac Resynchronization Therapy in Patients With a Non-Left Bundle Branch Block Morphology. American Journal of Cardiology, 2011, 108, 1576-1580.	0.7	45
239	Immunoglobulins Against Tyrosine-Nitrated Epitopes in Coronary Artery Disease. Circulation, 2012, 126, 2392-2401.	1.6	45
240	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. American Heart Journal, 2012, 164, 616-624.	1.2	45
241	Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: Fate of â€œnonrespondersâ€• Heart Rhythm, 2014, 11, 412-416.	0.3	45
242	Liver function tests in patients with acute heart failure and associated outcomes: insights from <scp>ASCENDâ€HF</scp>. European Journal of Heart Failure, 2016, 18, 424-432.	2.9	45
243	Prognostic Value of Baseline and ChangesÂin Circulating Soluble ST2 LevelsÂand the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 68-77.	1.9	45
244	Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. Cardiovascular Research, 2022, 118, 2367-2384.	1.8	45
245	A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. American Heart Journal, 2015, 169, 806-812.	1.2	44
246	Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). American Journal of Cardiology, 2017, 119, 78-83.	0.7	44
247	Metabolic Biomarkers in Heart Failure. Heart Failure Clinics, 2018, 14, 109-118.	1.0	44
248	QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Heart Rhythm, 2013, 10, 55-60.	0.3	43
249	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circulation: Heart Failure, 2019, 12, e005552.	1.6	43
250	Recent Insights Into the Role of Autoimmunity in Idiopathic Dilated Cardiomyopathy. Journal of Cardiac Failure, 2008, 14, 521-530.	0.7	42
251	Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure. American Journal of Cardiology, 2009, 103, 1113-1119.	0.7	42
252	Genetic contribution of the leukotriene pathway to coronary artery disease. Human Genetics, 2011, 129, 617-627.	1.8	42

#	Article	IF	Citations
253	Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension. Respiratory Research, 2013, 14, 6.	1.4	42
254	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.	1.6	42
255	Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 123.	1.6	42
256	Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. European Journal of Heart Failure, 2019, 21, 634-642.	2.9	42
257	Urinary Sodium Profiling in Chronic HeartÂFailure to Detect Development of Acute Decompensated Heart Failure. JACC: Heart Failure, 2019, 7, 404-414.	1.9	42
258	Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. Journal of Lipid Research, 2020, 61, 159-177.	2.0	42
259	Risk Prediction with Serial Myeloperoxidase Monitoring in Patients with Acute Chest Pain. Clinical Chemistry, 2011, 57, 1762-1770.	1.5	41
260	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.	1.6	41
261	Prognostic Value of Estimating Functional Capacity With the Use of the Duke Activity Status Index in Stable Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2015, 21, 44-50.	0.7	41
262	Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. Molecular Genetics and Metabolism, 2016, 119, 187-206.	0.5	41
263	Association of a Genetic Risk Score With Prevalent and Incident Myocardial Infarction in Subjects Undergoing Coronary Angiography. Circulation: Cardiovascular Genetics, 2012, 5, 441-449.	5.1	40
264	Targeting the Microbiome in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 27.	0.4	40
265	Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease. Seminars in Nephrology, 2018, 38, 193-205.	0.6	40
266	Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy. American Heart Journal, 2011, 162, 262-267.e3.	1.2	39
267	Dissociation of Objective and Subjective Daytime Sleepiness and Biomarkers of Systemic Inflammation in Sleep-Disordered Breathing and Systolic Heart Failure. Journal of Clinical Sleep Medicine, 2017, 13, 1411-1422.	1.4	39
268	Longitudinal Plasma Measures of Trimethylamine Nâ€Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Communityâ€Based Older Adults. Journal of the American Heart Association, 2021, 10, e020646.	1.6	39
269	Prognostic Value of Elevated Serum Ceruloplasmin Levels in Patients With Heart Failure. Journal of Cardiac Failure, 2014, 20, 946-952.	0.7	38
270	Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	38

#	Article	IF	Citations
271	The Chromosome 9p21.3 Coronary Heart Disease Risk Allele Is Associated with Altered Gene Expression in Normal Heart and Vascular Tissues. PLoS ONE, 2012, 7, e39574.	1.1	37
272	Precision of Echocardiographic Estimates of Right Atrial Pressure in Patients with Acute Decompensated Heart Failure. Journal of the American Society of Echocardiography, 2014, 27, 1072-1078.e2.	1.2	37
273	Prognostic Comparison of Different Sensitivity Cardiac Troponin Assays in Stable Heart Failure. American Journal of Medicine, 2015, 128, 276-282.	0.6	37
274	Management of Cardio-Renal Syndrome and Diuretic Resistance. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 11.	0.4	37
275	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	1.2	37
276	Misinformation Dissemination in Twitter in the COVID-19 Era. American Journal of Medicine, 2020, 133, 1367-1369.	0.6	37
277	PPAR? agonists: safety issues in heart failure. Diabetes, Obesity and Metabolism, 2007, 9, 447-454.	2.2	36
278	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCENDâ€HF. European Journal of Heart Failure, 2016, 18, 306-313.	2.9	36
279	The microbial gbu gene cluster links cardiovascular disease risk associated with red meat consumption to microbiota l-carnitine catabolism. Nature Microbiology, 2022, 7, 73-86.	5.9	36
280	Comorbidity Significantly Affects Clinical Outcome After Cardiac Resynchronization Therapy Regardless of Ventricular Remodeling. Journal of Cardiac Failure, 2012, 18, 845-853.	0.7	35
281	Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. European Journal of Heart Failure, 2015, 17, 689-696.	2.9	35
282	Comparative Assessment of Short-TermÂAdverse Events in Acute Heart Failure WithÂCystatin C andÂOther Estimates ofÂRenal Function. JACC: Heart Failure, 2015, 3, 40-49.	1.9	35
283	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 2016, 22, 884-890.	0.7	35
284	B-type natriuretic peptide and echocardiography reflect volume changes during pregnancy. Journal of Perinatal Medicine, 2017, 45, 577-583.	0.6	35
285	Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. American Heart Journal, 2021, 236, 80-86.	1.2	35
286	Aspirin Hydrolysis in Plasma Is a Variable Function of Butyrylcholinesterase and Platelet-activating Factor Acetylhydrolase 1b2 (PAFAH1b2). Journal of Biological Chemistry, 2013, 288, 11940-11948.	1.6	34
287	Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure. Circulation: Heart Failure, 2016, 9, e002115.	1.6	34
288	Metabolic and Functional Evaluation of the Heart and Lungs in Pulmonary Hypertension by Gated 2â€[18F]â€Fluoroâ€2â€deoxyâ€Dâ€glucose Positron Emission Tomography. Pulmonary Circulation, 2017, 7, 428-438.	0.8	34

#	Article	IF	Citations
289	Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clinical Biochemistry, 2017, 50, 491-495.	0.8	34
290	Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 119, 65-70.	0.7	34
291	A common variant alters SCN5Aâ€“miR-24 interaction and associates with heart failure mortality. Journal of Clinical Investigation, 2018, 128, 1154-1163.	3.9	34
292	Do thiazolidinediones cause heart failure? A critical review.. Cleveland Clinic Journal of Medicine, 2006, 73, 390-397.	0.6	34
293	Threshold crossing of device-based intrathoracic impedance trends identifies relatively increased mortality risk. European Heart Journal, 2012, 33, 2189-2196.	1.0	33
294	Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients. American Journal of Cardiology, 2014, 113, 1893-1898.	0.7	33
295	The rs11515 Polymorphism Is More Frequent and Associated With Aggressive Breast Tumors with Increased ANRIL and Decreased p16INK4a Expression. Frontiers in Oncology, 2016, 5, 306.	1.3	33
296	Machine Learningâ€“Based Risk Assessment for Cancer Therapyâ€“Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients. Journal of the American Heart Association, 2020, 9, e019628.	1.6	33
297	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	0.8	32
298	Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. JAMA Network Open, 2020, 3, e204296.	2.8	32
299	Peroxisome proliferatorâ€“activated receptor Î³ agonists for the Prevention of Adverse events following percutaneous coronary Revascularizationâ€”results of the PPAR Study. American Heart Journal, 2007, 154, 137-143.	1.2	31
300	Impact of left ventricular volume/mass ratio on diastolic function. European Heart Journal, 2009, 30, 1213-1221.	1.0	31
301	Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism. Free Radical Biology and Medicine, 2012, 53, 230-236.	1.3	31
302	Diminished Global Arginine Bioavailability as a Metabolic Defect in Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2013, 19, 87-93.	0.7	31
303	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. Journal of Cardiac Failure, 2018, 24, 428-438.	0.7	31
304	Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. European Journal of Heart Failure, 2018, 20, 1436-1443.	2.9	31
305	Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure. Mayo Clinic Proceedings, 2005, 80, 1623-1630.	1.4	30
306	Protein Carbamylation in Chronic Systolic Heart Failure: Relationship With Renal Impairment and Adverse Long-Term Outcomes. Journal of Cardiac Failure, 2013, 19, 219-224.	0.7	30

#	Article	IF	Citations
307	Rationale and Design of the ATHENA-HF Trial. JACC: Heart Failure, 2016, 4, 726-735.	1.9	30
308	Association Between Egg Consumption and Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. American Journal of Medicine, 2021, 134, 76-83.e2.	0.6	30
309	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nature Reviews Cardiology, 2009, 6, 349-355.	6.1	29
310	Efficacy of the CHADS2 Scoring System to Assess Left Atrial Thrombogenic Milieu Risk Before Cardioversion of Non-Valvular Atrial Fibrillation. American Journal of Cardiology, 2013, 112, 678-683.	0.7	29
311	Cardiac Resynchronization Therapy in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1293-1303.	2.2	29
312	Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients. Journal of the American Heart Association, 2014, 3, e000960.	1.6	29
313	Low cardiac output associated with ventricular tachyarrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). Journal of Heart and Lung Transplantation, 2014, 33, 318-320.	0.3	29
314	Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Progress in Cardiovascular Diseases, 2004, 47, 196-206.	1.6	28
315	Pharmacologic Strategies to Target Oxidative Stress in Heart Failure. Current Heart Failure Reports, 2012, 9, 14-22.	1.3	28
316	Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against Î² 1 -Adrenergic Receptors. Journal of the American College of Cardiology, 2017, 69, 968-977.	1.2	28
317	QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm, 2012, 9, 1674-1678.	0.3	27
318	Highâ€ddensity lipoproteinâ€associated paraoxonaseâ€1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. European Journal of Heart Failure, 2017, 19, 748-755.	2.9	27
319	An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. International Journal of Cardiology, 2017, 241, 277-282.	0.8	27
320	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. Circulation: Heart Failure, 2020, 13, e006363.	1.6	27
321	Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology, 2004, 43, 542-548.	1.2	26
322	Why do patients fail to receive Î²-blockers for chronic heart failure over time? A â€œreal-worldâ€• single-center, 2-year follow-up experience of Î²-blocker therapy in patients with chronic heart failure. American Heart Journal, 2005, 149, 921-926.	1.2	26
323	Prognostic Evaluation of Ambulatory Patients With Advanced Heart Failure. American Journal of Cardiology, 2008, 101, 1297-1302.	0.7	26
324	Epidemiology of Anemia in Heart Failure. Heart Failure Clinics, 2010, 6, 271-278.	1.0	26

#	Article	IF	Citations
325	Association Between Systemic Neutrophil Gelatinaseâ€“Associated Lipocalin and Anemia, Relative Hypochromia, and Inflammation in Chronic Systolic Heart Failure. Congestive Heart Failure, 2012, 18, 239-244.	2.0	26
326	Diminished Antioxidant Activity of Highâ€Density Lipoproteinâ€“Associated Proteins in Chronic Kidney Disease. Journal of the American Heart Association, 2013, 2, .	1.6	26
327	Coenzyme Q supplementation in pulmonary arterial hypertension. Redox Biology, 2014, 2, 884-891.	3.9	26
328	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. Journal of the American College of Cardiology, 2015, 66, 2618-2629.	1.2	26
329	Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling. Circulation: Cardiovascular Imaging, 2018, 11, e007813.	1.3	26
330	Genetic, dietary, and sex-specific regulation of hepatic ceramides and the relationship between hepatic ceramides and IR [S]. Journal of Lipid Research, 2018, 59, 1164-1174.	2.0	26
331	Impact of bariatric surgery on heart failure mortality. Surgery for Obesity and Related Diseases, 2019, 15, 1189-1196.	1.0	26
332	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 101-107.	0.7	26
333	The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. Archives of Internal Medicine, 2001, 161, 667.	4.3	25
334	Increasing Serum Soluble Angiotensin-Converting Enzyme 2 Activity After Intensive Medical Therapy Is Associated With Better Prognosis in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2013, 19, 605-610.	0.7	25
335	Renin-Angiotensin-Aldosterone System Activation During Decongestion in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 108-111.	1.9	25
336	Influence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure. Circulation: Heart Failure, 2016, 9, e002333.	1.6	25
337	Virtual Versus In-Person Visits and Appointment No-Show Rates in Heart Failure Care Transitions. Circulation: Heart Failure, 2020, 13, e007119.	1.6	25
338	Right Heart Failure and Cardiorenal Syndrome. Cardiology Clinics, 2020, 38, 185-202.	0.9	25
339	Biomarkers: Their potential in the diagnosis and treatment of heart failure. Cleveland Clinic Journal of Medicine, 2015, 82, S28-S35.	0.6	25
340	Vasopressin Receptor Antagonists. JAMA - Journal of the American Medical Association, 2004, 291, 2017.	3.8	24
341	Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America, 2004, 88, 1037-1061.	1.1	24
342	Design and Organization of the Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT) Trial: a factorial trial evaluating the effects of corticosteroids, glucose control, and depth-of-anesthesia on perioperative inflammation and morbidity from major non-cardiac surgery. BMC Anesthesiology, 2010, 10, 11.	0.7	24

#	Article	IF	Citations
343	Subclinical Myocardial Necrosis and Cardiovascular Risk in Stable Patients Undergoing Elective Cardiac Evaluation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 634-640.	1.1	24
344	The impact of left ventricular size on response to cardiac resynchronization therapy. American Heart Journal, 2011, 162, 646-653.	1.2	24
345	High Levels of Zinc-Protoporphyrin Identify Iron Metabolic Abnormalities in Pulmonary Arterial Hypertension. Clinical and Translational Science, 2011, 4, 253-258.	1.5	24
346	Inflammation and cardioâ€renal interactions in heart failure: a potential role for interleukinâ€6. European Journal of Heart Failure, 2018, 20, 933-934.	2.9	24
347	Serum Chloride Levels Track With SurvivalÂin Patients With Pulmonary ArterialÂHypertension. Chest, 2018, 154, 541-549.	0.4	24
348	Fish Consumption and Cardiovascular Health: A Systematic Review. American Journal of Medicine, 2021, 134, 713-720.	0.6	24
349	Gender Differences in Patients Admitted With Advanced Decompensated Heart Failure. American Journal of Cardiology, 2008, 102, 454-458.	0.7	23
350	Myeloperoxidase in Cardiovascular Disease. Advances in Clinical Chemistry, 2013, 62, 1-32.	1.8	23
351	Uptitration of Renin-Angiotensin System Blocker and Beta-Blocker Therapy in Patients Hospitalized for Heart Failure With Reduced Versus Preserved Left Ventricular Ejection Fractions. American Journal of Cardiology, 2013, 112, 1913-1920.	0.7	23
352	Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis. Current Diabetes Reports, 2015, 15, 63.	1.7	23
353	Lamin A/C Cardiomyopathies: Current Understanding and Novel Treatment Strategies. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 21.	0.4	23
354	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. European Journal of Heart Failure, 2022, 24, 169-180.	2.9	23
355	Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HF. Current Heart Failure Reports, 2011, 8, 7-13.	1.3	22
356	Potential Effects of Digoxin on Long-Term Renal and Clinical Outcomes in Chronic Heart Failure. Journal of Cardiac Failure, 2013, 19, 295-302.	0.7	22
357	Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortia. Human Molecular Genetics, 2013, 22, 3381-3393.	1.4	22
358	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <scp>ASCENDâ€HF</scp>. European Journal of Heart Failure, 2015, 17, 340-346.	2.9	22
359	Insufficient reduction in heart rate during hospitalization despite betaâ€blocker treatment in acute decompensated heart failure: insights from the ASCENDâ€HF trial. European Journal of Heart Failure, 2017, 19, 241-249.	2.9	22
360	Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. Nature Communications, 2019, 10, 2760.	5.8	22

#	Article	IF	Citations
361	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
362	Improved Algorithm to Detect Fluid Accumulation via Intrathoracic Impedance Monitoring in Heart Failure Patients With Implantable Devices. Journal of Cardiac Failure, 2011, 17, 569-576.	0.7	21
363	Integrating Plasma High-Sensitivity C-Reactive Protein and Myeloperoxidase for Risk Prediction in Chronic Systolic Heart Failure. Congestive Heart Failure, 2011, 17, 105-109.	2.0	21
364	Survival of Patients With Biventricular Devices After Device Infection, Extraction, and Reimplantation. JACC: Heart Failure, 2013, 1, 508-513.	1.9	21
365	Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy. Europace, 2013, 15, 1747-1756.	0.7	21
366	Outcomes of Infected Cardiovascular Implantable Devices in Dialysis Patients. American Journal of Nephrology, 2014, 40, 280-287.	1.4	21
367	Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na+/K+-ATPase Profibrotic Signaling Pathways. International Journal of Molecular Sciences, 2018, 19, 2566.	1.8	21
368	Paraoxonase 2 prevents the development of heart failure. Free Radical Biology and Medicine, 2018, 121, 117-126.	1.3	21
369	Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiologica, 2019, 74, 100-107.	0.3	21
370	Reappraisal of Inflammatory Biomarkers in Heart Failure. Current Heart Failure Reports, 2020, 17, 9-19.	1.3	21
371	Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2020, 75, 1426-1438.	1.2	21
372	Digital Health Applications in Heart Failure: a Critical Appraisal of Literature. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 12.	0.4	21
373	MicroRNAâ€574 regulates FAM210A expression and influences pathological cardiac remodeling. EMBO Molecular Medicine, 2021, 13, e12710.	3.3	21
374	Cardiogenic shock: From ECMO to Impella and beyond. Cleveland Clinic Journal of Medicine, 2017, 84, 287-295.	0.6	21
375	Pathophysiology of congestive heart failure. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 2, S14-20.	0.5	21
376	Clinical Significance of Endogenous Vasoactive Neurohormones in Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2010, 16, 635-640.	0.7	20
377	Role of Oxidative Stress in Disease Progression in Stage B, a Pre-cursor of Heart Failure. Heart Failure Clinics, 2012, 8, 101-111.	1.0	20
378	Prognostic Implications of Relative Hypochromia in Ambulatory Patients With Chronic Systolic Heart Failure. Congestive Heart Failure, 2013, 19, 180-185.	2.0	20

#	Article	IF	Citations
379	Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. Heart Rhythm, 2015, 12, 517-523.	0.3	20
380	Utilizing Cardiac Biomarkers to Detect and Prevent Chemotherapy-Induced Cardiomyopathy. Current Heart Failure Reports, 2015, 12, 255-262.	1.3	20
381	Autoantibodies Specifically Against Î²1 Adrenergic Receptors and Adverse Clinical Outcome in Patients With Chronic Systolic Heart Failure in the Î²-Blocker Era: The Importance of Immunoglobulin G3 Subclass. Journal of Cardiac Failure, 2016, 22, 417-422.	0.7	20
382	Amyloid heart disease: genetics translated into disease-modifying therapy. Heart, 2017, 103, 812-817.	1.2	20
383	Genetic Determinants of Circulating Glycine Levels and Risk of Coronary Artery Disease. Journal of the American Heart Association, 2019, 8, e011922.	1.6	20
384	Digoxin Use in Cardiac Amyloidosis. American Journal of Cardiology, 2020, 133, 134-138.	0.7	20
385	HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans. Heart, 2020, 106, 147-153.	1.2	20
386	Myeloperoxidase: a potential therapeutic target for coronary artery disease. Expert Opinion on Therapeutic Targets, 2020, 24, 695-705.	1.5	20
387	CARDIOMYOPATHY AND HEART FAILURE IN DIABETES. Endocrinology and Metabolism Clinics of North America, 2001, 30, 1031-1046.	1.2	19
388	Statin treatment for patients with heart failure. Nature Reviews Cardiology, 2010, 7, 249-255.	6.1	19
389	Right Ventricular Afterload and the Role of Nitric Oxide Metabolism in Left-Sided Heart Failure. Journal of Cardiac Failure, 2013, 19, 712-721.	0.7	19
390	Utilization Pattern of Mineralocorticoid Receptor Antagonists in Contemporary Patients Hospitalized With Acute Decompensated Heart Failure: A Single-Center Experience. Journal of Cardiac Failure, 2014, 20, 229-235.	0.7	19
391	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 777-785.	1.9	19
392	Focal fibrosis and diffuse fibrosis are predictors of reversed left ventricular remodeling in patients with non-ischemic cardiomyopathy. International Journal of Cardiology, 2016, 221, 498-504.	0.8	19
393	Transient Hyponatremia During Hospitalization for Acute Heart Failure. American Journal of Medicine, 2016, 129, 620-627.	0.6	19
394	Echocardiographic Predictors of Longâ€Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric?. Journal of Cardiovascular Electrophysiology, 2017, 28, 410-415.	0.8	19
395	Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2017, 18, 147032031772991.	1.0	19
396	Correlation of Highâ€Density Lipoproteinâ€“Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. Arthritis and Rheumatology, 2018, 70, 1240-1250.	2.9	19

#	Article	IF	Citations
397	Cardiac risk stratification in cancer patients: A longitudinal patientâ€“patient network analysis. PLoS Medicine, 2021, 18, e1003736.	3.9	19
398	Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. American Heart Journal, 2004, 148, 889-894.	1.2	18
399	Using echocardiography in cardiac resynchronization therapy. American Heart Journal, 2007, 154, 1011-1020.	1.2	18
400	Increased Exhaled Nitric Oxide Levels After Exercise in Patients With Chronic Systolic Heart Failure With Pulmonary Venous Hypertension. Journal of Cardiac Failure, 2012, 18, 799-803.	0.7	18
401	Plasma Ceruloplasmin, a Regulator of Nitric Oxide Activity, and Incident Cardiovascular Risk in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 462-467.	2.2	18
402	Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2015, 17, 320-328.	2.9	18
403	Long-term dietary habits and interventions in solid-organ transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1357-1365.	0.3	18
404	Big data, artificial intelligence, and cardiovascular precision medicine. Expert Review of Precision Medicine and Drug Development, 2018, 3, 305-317.	0.4	18
405	How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology. Personalized Medicine, 2019, 16, 87-92.	0.8	18
406	Dynamic Assessment of Pulmonary Artery Pulsatility Index Provides Incremental Risk Assessment for Early Right Ventricular Failure After Left Ventricular Assist Device. Journal of Cardiac Failure, 2021, 27, 777-785.	0.7	18
407	Drug Insight: aldosterone-receptor antagonists in heart failureâ€”the journey continues. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 368-378.	3.3	17
408	B-Type Natriuretic Peptide: A Critical Review. Congestive Heart Failure, 2007, 13, 48-52.	2.0	17
409	Comprehensive Peroxidase-Based Hematologic Profiling for the Prediction of 1-Year Myocardial Infarction and Death. Circulation, 2010, 122, 70-79.	1.6	17
410	Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence?. Current Heart Failure Reports, 2014, 11, 500-508.	1.3	17
411	Prognostic Value of Glomerular Filtration Changes Versus Natriuretic Response in Decompensated Heart Failure With Reduced Ejection. Journal of Cardiac Failure, 2014, 20, 817-824.	0.7	17
412	Effect of PR interval prolongation on long-term outcomes in patients with left bundle branch block vs nonâ€“left bundle branch block morphologies undergoing cardiac resynchronization therapy. Heart Rhythm, 2017, 14, 1523-1528.	0.3	17
413	Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure. Journal of Cardiac Failure, 2017, 23, 138-144.	0.7	17
414	Protecting the heart in cancer therapy. F1000Research, 2018, 7, 1566.	0.8	17

#	Article	IF	Citations
415	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
416	Artificial Intelligence and Hypertension: Recent Advances and Future Outlook. American Journal of Hypertension, 2020, 33, 967-974.	1.0	17
417	Î²-Blockers and reverse remodeling: What are the implications?. American Heart Journal, 2003, 145, 200-202.	1.2	16
418	Insights From Internetâ€Based Remote Intrathoracic Impedance Monitoring as Part of a Heart Failure Disease Management Program. Congestive Heart Failure, 2010, 16, 159-163.	2.0	16
419	Device monitoring strategies in acute heart failure syndromes. Heart Failure Reviews, 2011, 16, 491-502.	1.7	16
420	Reconsidering Ultrafiltration in the Acute Cardiorenal Syndrome. New England Journal of Medicine, 2012, 367, 2351-2352.	13.9	16
421	Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart, 2013, 99, 314-319.	1.2	16
422	Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Current Heart Failure Reports, 2017, 14, 106-116.	1.3	16
423	Navigating air travel and cardiovascular concerns: Is the sky the limit?. Clinical Cardiology, 2017, 40, 660-666.	0.7	16
424	Peripheral Venous Pressure Measurements in Patients With Acute Decompensated Heart Failure (PVP-HF). Circulation: Heart Failure, 2017, 10, .	1.6	16
425	Therapeutic Strategies Targeting Inherited Cardiomyopathies. Current Heart Failure Reports, 2017, 14, 321-330.	1.3	16
426	Body Mass Index, Natriuretic Peptides, and Risk of Adverse OutcomesÂin Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial. Journal of the American Heart Association, 2018, 7, e009664.	1.6	16
427	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512.	0.7	16
428	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676.	0.7	16
429	Cardiorenal Syndrome: Diagnosis, Treatment, and Clinical Outcomes. Current Heart Failure Reports, 2010, 7, 167-174.	1.3	15
430	Usefulness of Cardiac Biomarker Score for Risk Stratification in Stable Patients Undergoing Elective Cardiac Evaluation Across Glycemic Status. American Journal of Cardiology, 2013, 111, 465-470.	0.7	15
431	Long-Term Outcomes in Patients With Ambulatory New York Heart Association Class III and IV Heart Failure Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2015, 115, 82-85.	0.7	15
432	Impacto de la microbiota intestinal en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2017, 70, 799-800.	0.6	15

#	Article	IF	Citations
433	Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. Heart Rhythm, 2018, 15, 130-136.	0.3	15
434	Dermal Interstitial Alterations in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2018, 11, e004763.	1.6	15
435	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. Circulation: Heart Failure, 2020, 13, e006827.	1.6	15
436	Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007931.	1.6	15
437	POLYPHARMACY OF HEART FAILURE. Cardiology Clinics, 2001, 19, 583-596.	0.9	14
438	Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal proâ€“B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. American Heart Journal, 2007, 153, 36-41.	1.2	14
439	The Year in Heart Failure. Journal of the American College of Cardiology, 2010, 55, 688-696.	1.2	14
440	Pharmacologic Management of Chronic Reno-Cardiac Syndrome. Current Heart Failure Reports, 2013, 10, 54-62.	1.3	14
441	Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms. Journal of Heart and Lung Transplantation, 2015, 34, 390-394.	0.3	14
442	Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing. Endocrinology, 2016, 157, 4865-4874.	1.4	14
443	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. Frontiers in Cardiovascular Medicine, 2021, 8, 721333.	1.1	14
444	Fecal Microbiome Composition Does Not Predict Dietâ€Induced TMAO Production in Healthy Adults. Journal of the American Heart Association, 2021, 10, e021934.	1.6	14
445	Circulating trimethylamine N-oxide levels following fish or seafood consumption. European Journal of Nutrition, 2022, 61, 2357-2364.	1.8	14
446	The effect of intravenous ferric carboxymaltose on right ventricular function â€“ insights from the <scp>IRONâ€CRT</scp> trial. European Journal of Heart Failure, 2022, 24, 1106-1113.	2.9	14
447	The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Human Genetics, 2010, 127, 101-105.	1.8	13
448	Plasma Corin Levels Provide Minimal Prognostic Utility Incremental to Natriuretic Peptides in Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2010, 16, 621-627.	0.7	13
449	Biomarkers in Advanced Heart Failure: Diagnostic and Therapeutic Insights. Congestive Heart Failure, 2011, 17, 169-174.	2.0	13
450	Impact of Left Ventricular Diastolic Function on Left Atrial Mechanics in Systolic Heart Failure. American Journal of Cardiology, 2013, 112, 821-826.	0.7	13

#	Article	IF	Citations
451	Genetic and Nongenetic Factors Influencing Pharmacokinetics of B-Type Natriuretic Peptide. Journal of Cardiac Failure, 2014, 20, 662-668.	0.7	13
452	Dietary metabolism, gut microbiota and acute heart failure. Heart, 2016, 102, 813-814.	1.2	13
453	Relation of Red Cell Distribution Width to Left Ventricular End-Diastolic Pressure and Mortality in Patients With and Without Heart Failure. American Journal of Cardiology, 2017, 119, 1421-1427.	0.7	13
454	Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.7	13
455	Impact of early treatment with intravenous vasodilators and blood pressure reduction in acute heart failure. Open Heart, 2018, 5, e000845.	0.9	13
456	Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI Insight, 2021, 6, .	2.3	13
457	Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial. American Journal of Medicine, 2021, 134, 1160-1169.e3.	0.6	13
458	Artificial Intelligence and Cardiovascular Genetics. Life, 2022, 12, 279.	1.1	13
459	Burden of Pediatric HeartÂFailure in the United States. Journal of the American College of Cardiology, 2022, 79, 1917-1928.	1.2	13
460	Association of Trimethylamine N-Oxide and Metabolites With Mortality in Older Adults. JAMA Network Open, 2022, 5, e2213242.	2.8	13
461	Novel pharmacological treatments for heart failure. Expert Opinion on Investigational Drugs, 2003, 12, 1791-1801.	1.9	12
462	The Difficult Task of Evaluating How to Monitor Patients With Heart Failure. Journal of Cardiac Failure, 2005, 11, 422-424.	0.7	12
463	Management of Comorbid Conditions in Heart Failure. Medical Clinics of North America, 2012, 96, 975-985.	1.1	12
464	Evolving Approaches to Genetic Evaluation of Specific Cardiomyopathies. Current Heart Failure Reports, 2015, 12, 339-349.	1.3	12
465	Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 8-10.	3.0	12
466	Advances in new therapeutic targets for atherosclerosis. Nature Reviews Cardiology, 2017, 14, 71-72.	6.1	12
467	Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDAÂApproval. JACC: Heart Failure, 2017, 5, 460-463.	1.9	12
468	Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. International Journal of Cardiology, 2018, 252, 112-116.	0.8	12

#	Article	IF	Citations
469	Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 68-77.	3.0	12
470	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENAâ€HF trial. European Journal of Heart Failure, 2020, 22, 1451-1461.	2.9	12
471	Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy. Journal of Cardiac Failure, 2021, 27, 368-372.	0.7	12
472	Novel Approach to Risk Stratification in Left Ventricular Nonâ€Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach. Journal of the American Heart Association, 2021, 10, e019209.	1.6	12
473	Familial hypercholesterolemia: Detect, treat, and ask about family. Cleveland Clinic Journal of Medicine, 2020, 87, 109-120.	0.6	12
474	Comparative sensitivities betweendifferent plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clinical Cornerstone, 2005, 7, S18-S24.	1.0	11
475	The Year in Heart Failure. Journal of the American College of Cardiology, 2007, 50, 2344-2351.	1.2	11
476	Lack of Concordance in Defining Worsening Renal Function by Rise in Creatinine vs Rise in Cystatin <scp>C</scp>. Congestive Heart Failure, 2013, 19, E17-21.	2.0	11
477	Recent advances in treatment of heart failure. F1000Research, 2015, 4, 1475.	0.8	11
478	The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft Survival: Insights Into Reno-Cardiac Interactions. Journal of Cardiac Failure, 2016, 22, 368-375.	0.7	11
479	Impact of Ultrafiltration on Serum Sodium Homeostasis and its Clinical Implication in Patients With Acute Heart Failure, Congestion, and Worsening Renal Function. Circulation: Heart Failure, 2017, 10, e003603.	1.6	11
480	The Role and Impact of Gut Microbiota in Cardiovascular Disease. Revista Espanola De Cardiologia (English Ed), 2017, 70, 799-800.	0.4	11
481	Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low. Acta Cardiologica, 2018, 73, 335-341.	0.3	11
482	Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 1707-1711.	0.7	11
483	Prognostic Implications of Changes in Amino-Terminal Proâ€“B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. Journal of Cardiac Failure, 2019, 25, 703-711.	0.7	11
484	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
485	Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?. Current Diabetes Reports, 2020, 20, 75.	1.7	11
486	Global analysis of histone modifications and long-range chromatin interactions revealed the differential cistrome changes and novel transcriptional players in human dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2020, 145, 30-42.	0.9	11

#	Article	IF	Citations
487	Gut Microbiome and Precision Nutrition in Heart Failure: Hype or Hope?. Current Heart Failure Reports, 2021, 18, 23-32.	1.3	11
488	Mitochondrial DNA Content Is Linked to Cardiovascular Disease Patient Phenotypes. Journal of the American Heart Association, 2021, 10, e018776.	1.6	11
489	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
490	Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?. Current Heart Failure Reports, 2022, 19, 180-190.	1.3	11
491	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. American Journal of Cardiology, 2002, 90, 1198-1203.	0.7	10
492	The Year in Heart Failure. Journal of the American College of Cardiology, 2005, 46, 2125-2133.	1.2	10
493	Mechanical dyssynchrony in advanced decompensated heart failure: Relation to hemodynamic responses to intensive medical therapy. Heart Rhythm, 2008, 5, 1105-1110.	0.3	10
494	Optimizing Cardiac Resynchronization Therapy in Advanced Heart Failure. Congestive Heart Failure, 2011, 17, 147-151.	2.0	10
495	Detectable Subclinical Myocardial Necrosis Is Associated With Cardiovascular Risk in Stable Patients With Diabetes. Diabetes Care, 2013, 36, 1126-1131.	4.3	10
496	Usefulness of Relative Hypochromia in Risk Stratification for Nonanemic Patients With Chronic Heart Failure. American Journal of Cardiology, 2016, 117, 1299-1304.	0.7	10
497	Left Ventricular Size does not Modify the Effect of QRS Duration in Predicting Response to Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 482-487.	0.5	10
498	Discordance between 'actual' and 'scheduled' check-in times at a heart failure clinic. PLoS ONE, 2017, 12, e0187849.	1.1	10
499	Relative quantification of betaâ€adrenergic receptor in peripheral blood cells using flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 563-570.	1.1	10
500	Utility of the Psychosocial Assessment of Candidates for Transplantation in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. Progress in Transplantation, 2018, 28, 220-225.	0.4	10
501	Genetic Reduction in Left Ventricular Protein Kinase C-Î± and Adverse Ventricular Remodeling in Human Subjects. Circulation Genomic and Precision Medicine, 2018, 11, e001901.	1.6	10
502	Soluble angiotensin converting enzyme 2 levels in chronic heart failure is associated with decreased exercise capacity and increased oxidative stress-mediated endothelial dysfunction. Translational Research, 2019, 212, 80-88.	2.2	10
503	RNA Sequence Analyses throughout the Course of Mouse Cardiac Laminopathy Identify Differentially Expressed Genes for Cell Cycle Control and Mitochondrial Function. Scientific Reports, 2020, 10, 6632.	1.6	10
504	Cardiac magnetic resonance fingerprinting: Trends in technical development and potential clinical applications. Progress in Nuclear Magnetic Resonance Spectroscopy, 2021, 122, 11-22.	3.9	10

#	Article	IF	Citations
505	Cystatin C and Muscle Mass in Patients With Heart Failure. Journal of Cardiac Failure, 2021, 27, 48-56.	0.7	10
506	Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes. Cardiovascular Diabetology, 2021, 20, 171.	2.7	10
507	Three Healthy Eating Patterns and Cardiovascular Disease Risk Markers in 9 to 18 Year Olds With Body Mass Index >95%: A Randomized Trial. Clinical Pediatrics, 2021, 60, 474-484.	0.4	10
508	Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008877.	1.6	10
509	Stable isotope dilution mass spectrometry quantification of hydrogen sulfide and thiols in biological matrices. Redox Biology, 2022, 55, 102401.	3.9	10
510	Spironolactone inchronic heart failure:allâ€™s well that ends well**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 41, 215-216.	1.2	9
511	Antiinflammatory Autoimmune Cellular Responses to Cardiac Troponin I in Idiopathic Dilated Cardiomyopathy. Journal of Cardiac Failure, 2011, 17, 359-365.	0.7	9
512	Indications for TEE Before Cardioversion for Atrial Fibrillation: Implications for Appropriateness Criteria. JACC: Cardiovascular Imaging, 2012, 5, 641-648.	2.3	9
513	Treatment Strategies for the Prevention of Heart Failure. Current Heart Failure Reports, 2013, 10, 331-340.	1.3	9
514	Nitric oxide bioavailability and adiponectin production in chronic systolic heart failure: relation to severity ofÂcardiac dysfunction. Translational Research, 2013, 162, 26-33.	2.2	9
515	Usefulness of Elevated Urine Neopterin Levels in Assessing Cardiac Dysfunction and Exercise Ventilation Inefficiency in Patients With Chronic Systolic Heart Failure. American Journal of Cardiology, 2014, 113, 1839-1843.	0.7	9
516	S100A1 in Human Heart Failure. Circulation: Heart Failure, 2014, 7, 612-618.	1.6	9
517	Renal Failure Requiring Dialysis Complicating Slow Continuous Ultrafiltration in Acute Heart Failure: Importance of Systolic Perfusion Pressure. Journal of Cardiac Failure, 2015, 21, 108-115.	0.7	9
518	MetaDiff: differential isoform expression analysis using random-effects meta-regression. BMC Bioinformatics, 2015, 16, 208.	1.2	9
519	Novel Insights and Treatment Strategies for Right Heart Failure. Current Heart Failure Reports, 2018, 15, 141-155.	1.3	9
520	The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patients. Archives of Medical Science, 2018, 14, 1003-1009.	0.4	9
521	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2018, 24, 512-519.	0.7	9
522	Initiation of Angiotensin Receptor-Neprilysin Inhibitor in HeartÂFailure With Low Cardiac Output. Journal of the American College of Cardiology, 2019, 74, 2326-2327.	1.2	9

#	Article	IF	Citations
523	Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure. Circulation, 2020, 142, 1055-1058.	1.6	9
524	Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances. Current Cardiology Reports, 2020, 22, 143.	1.3	9
525	Epithelial and Endothelial Adhesion of Immune Cells Is Enhanced by Cardiotonic Steroid Signaling Through Na ⁺ /K ⁺ â€ATPaseâ€Ìâ€1. Journal of the American Heart Association, 2020, 9, e013933.	1.6	9
526	Characterization of cardiac amyloidosis using cardiac magnetic resonance fingerprinting. International Journal of Cardiology, 2022, 351, 107-110.	0.8	9
527	Neurohormonal Upregulation in Heart Failure. Heart Failure Clinics, 2005, 1, 1-9.	1.0	8
528	Glycemic control and treatment patterns in patients with heart failure. Current Cardiology Reports, 2007, 9, 242-247.	1.3	8
529	Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. International Journal of Cardiology, 2016, 218, 136-143.	0.8	8
530	Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index. American Heart Journal, 2017, 184, 17-25.	1.2	8
531	Palliative Care in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 43.	0.4	8
532	Circulating NT-proBNP but not soluble corin levels were associated with preeclampsia in pregnancy-associated hypertension. Clinical Biochemistry, 2019, 67, 12-15.	0.8	8
533	Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 251-257.	0.7	8
534	Regulation of Na/K-ATPase expression by cholesterol: isoform specificity and the molecular mechanism. American Journal of Physiology - Cell Physiology, 2020, 319, C1107-C1119.	2.1	8
535	Association between chocolate consumption and risk of coronary artery disease: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, , 204748732093678.	0.8	8
536	Evidence of Stability in Patient-Reported Global Health During the COVID-19 Pandemic. Value in Health, 2021, 24, 1578-1585.	0.1	8
537	Renal sodium avidity, the prevailing renal target in heart failure. European Heart Journal, 2021, 42, 4478-4481.	1.0	8
538	The role of aldosterone receptor antagonists in the management of heart failure: An update. Cleveland Clinic Journal of Medicine, 2012, 79, 631-639.	0.6	8
539	Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. IJC Heart and Vasculature, 2020, 30, 100634.	0.6	8
540	Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade. Circulation, 2004, 110, 3618-3620.	1.6	7

#	Article	IF	Citations
541	The Year in Heart Failure. Journal of the American College of Cardiology, 2006, 48, 2575-2583.	1.2	7
542	Cardiac Resynchronization Therapy in New York Heart Association Class IV Heart Failure. Circulation, 2007, 115, 161-162.	1.6	7
543	Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. Future Cardiology, 2008, 4, 117-123.	0.5	7
544	Impact of Left Ventricular Remodeling on Diagnostic and Prognostic Value of Tissue Doppler Indices in Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2011, 17, 128-134.	0.7	7
545	Multispecialty approach: The need for heart failure disease management for refining cardiac resynchronization therapy. Heart Rhythm, 2012, 9, S45-S50.	0.3	7
546	Transesophageal Echocardiography and Cardioversion Trends in Patients with Atrial Fibrillation: A 10-Year Survey. Journal of the American Society of Echocardiography, 2012, 25, 962-968.	1.2	7
547	Clinical Outcomes After Tricuspid Valve Annuloplasty in Addition to Mitral Valve Surgery. Congestive Heart Failure, 2013, 19, 70-76.	2.0	7
548	Influence of Age-Related Versus Nonâ€“Age-Related Renal Dysfunction on Survival in Patients With Left Ventricular Dysfunction. American Journal of Cardiology, 2014, 113, 127-131.	0.7	7
549	Contemporary Insights and Novel Treatment Approaches to Central Sleep Apnea Syndrome in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 322.	0.4	7
550	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	7
551	Practical Pharmacogenomic Approaches to Heart Failure Therapeutics. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 60.	0.4	7
552	Validation of the Larissa Heart Failure Risk Score for risk stratification in acute heart failure. International Journal of Cardiology, 2020, 307, 119-124.	0.8	7
553	Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. Journal of Cardiac Failure, 2020, 26, 727-732.	0.7	7
554	Long-Term Outcomes in Patients With a Left Ejection FractionÂâ‰15% Undergoing CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 36-46.	1.3	7
555	Loop Diuretics Inhibit Renal Excretion of Trimethylamine N-Oxide. JACC Basic To Translational Science, 2021, 6, 103-115.	1.9	7
556	Whole-Transcriptome Profiling of Human Heart Tissues Reveals the Potential Novel Players and Regulatory Networks in Different Cardiomyopathy Subtypes of Heart Failure. Circulation Genomic and Precision Medicine, 2021, 14, e003142.	1.6	7
557	Invasive Hemodynamic and Metabolic Evaluation of HFpEF. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	7
558	A case series of cardiac amyloidosis patients supported by continuousâ€flow left ventricular assist device. ESC Heart Failure, 2021, 8, 4353-4356.	1.4	7

#	ARTICLE	IF	CITATIONS
559	Insights from Twitter about novel COVID-19 symptoms. European Heart Journal Digital Health, 2020, 1, 4-5.	0.7	7
560	Clinical Trials of Carvedilol in Heart Failure. Heart Failure Reviews, 1999, 4, 79-88.	1.7	6
561	Relation of mechanical dyssynchrony with underlying cardiac structure and performance in chronic systolic heart failure: implications on clinical response to cardiac resynchronization. Europace, 2008, 10, 1370-1374.	0.7	6
562	Early Cardiac Resynchronization Therapy and Reverse Remodeling in Patients With Mild Heart Failure. Circulation, 2009, 120, 1845-1846.	1.6	6
563	Impedance monitoring in heart failure: Are we really measuring hemodynamics?. American Heart Journal, 2009, 158, 152-153.	1.2	6
564	The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling. Current Pharmaceutical Design, 2009, 15, 850-856.	0.9	6
565	The Early Intertwining of the Heart and the Kidney Through an Impaired Natriuretic Response to Acute Volume Expansion. Journal of the American College of Cardiology, 2011, 58, 2104-2105.	1.2	6
566	Biomarkers of Acute Kidney Injury in Chronic Heart Failure. JACC: Heart Failure, 2013, 1, 425-426.	1.9	6
567	Natriuretic Peptide Testing in High-Risk Pregnancy: A Preventive Opportunity?. Current Heart Failure Reports, 2014, 11, 471-476.	1.3	6
568	Probiotic therapy to attenuate weight gain and trimethylamineâ€Nâ€Oxide generation: A cautionary tale. Obesity, 2015, 23, 2321-2322.	1.5	6
569	Response and tolerance to oral vasodilator upâ€titration after intravenous vasodilator therapy in advanced decompensated heart failure. European Journal of Heart Failure, 2015, 17, 956-963.	2.9	6
570	Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 13.	0.4	6
571	Implications of reninâ€angiotensinâ€system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. Clinical Cardiology, 2019, 42, 1010-1018.	0.7	6
572	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. European Heart Journal Cardiovascular Imaging, 2022, 23, 958-969.	0.5	6
573	Recent advances in hypertrophic cardiomyopathy. F1000prime Reports, 2014, 6, 12.	5.9	6
574	Differential expression of members of SOX family of transcription factors in failing human hearts. Translational Research, 2022, 242, 66-78.	2.2	6
575	Intestinal barrier dysfunction is associated with elevated right atrial pressure in patients with advanced decompensated heart failure. American Heart Journal, 2022, 245, 78-80.	1.2	6
576	Glycemic control and treatment patterns in patients with heart failure. Heart Failure Monitor, 2006, 5, 10-4.	0.7	6

#	Article	IF	Citations
577	Medical management of acute heart failure. Faculty Reviews, 2021, 10, 82.	1.7	6
578	Relation of Statin Use to Gut Microbial Trimethylamine N-Oxide and Cardiovascular Risk. American Journal of Cardiology, 2022, 178, 26-34.	0.7	6
579	Trends and Treatment of Heart Failure Developing After Acute Myocardial Infarction. The American Heart Hospital Journal, 2003, 1, 216-218.	0.2	5
580	Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opinion on Emerging Drugs, 2007, 12, 75-95.	1.0	5
581	The impact of diabetes on heart failure: Opportunities for intervention. Current Heart Failure Reports, 2007, 4, 70-77.	1.3	5
582	The Year in Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1671-1678.	1.2	5
583	Cardiac Resynchronization Therapy in Patients With Class Iâ€“II Heart Failure and a Wide QRS. Circulation, 2011, 123, 203-208.	1.6	5
584	Incorporating Common Biomarkers into the Clinical Management of Heart Failure. Current Heart Failure Reports, 2013, 10, 450-457.	1.3	5
585	A Clinical Prediction Rule to Identify Patients at Heightened Risk for Early Demise Following Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 278-282.	0.8	5
586	Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications. International Journal of Cardiology, 2017, 243, 318-325.	0.8	5
587	Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. American Heart Journal, 2017, 183, 35-39.	1.2	5
588	Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. Journal of the American Heart Association, 2018, 7, .	1.6	5
589	Intrarenal Venous Flow: A Distinct Cardiorenal Phenotype or Simply a Marker of Venous Congestion?. Journal of Cardiac Failure, 2021, 27, 35-39.	0.7	5
590	The IgG3 subclass of Î²1-adrenergic receptor autoantibodies is an endogenous biaser of Î²1AR signaling. Molecular Biology of the Cell, 2021, 32, 622-633.	0.9	5
591	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veteransâ€™ Health Administrative Database. CardioRenal Medicine, 2021, 11, 226-236.	0.7	5
592	Metabolic endophenotype associated with right ventricular glucose uptake in pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-12.	0.8	5
593	TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine Study. Genetics in Medicine, 2022, 24, 1495-1502.	1.1	5
594	Vasopressin receptor antagonists in the management of acute heart failure. Expert Opinion on Investigational Drugs, 2005, 14, 593-600.	1.9	4

#	Article	IF	Citations
595	Vasopressin Receptor Antagonists in Heart Failure. Recent Patents on Cardiovascular Drug Discovery, 2006, 1, 177-184.	1.5	4
596	Revisiting the cardioâ€renal hypothesis: the pivotal role of the kidney in congestive heart failure. European Journal of Heart Failure, 2011, 13, 820-822.	2.9	4
597	Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases. Heart Failure Reviews, 2014, 19, 295-304.	1.7	4
598	Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients. Journal of Cardiovascular Translational Research, 2015, 8, 545-553.	1.1	4
599	Comparison of Left Ventricular Torsion and Strain With Biventricular Pacing in Patients With Underlying Right Bundle Branch Block Versus Those With Left Bundle Branch Block. American Journal of Cardiology, 2015, 115, 918-923.	0.7	4
600	Reply. Journal of the American College of Cardiology, 2015, 66, 96-97.	1.2	4
601	We Are Not Alone. JACC: Heart Failure, 2016, 4, 228-229.	1.9	4
602	Meta-Analysis Comparing Frequency of Overweight Versus Normal Weight in Patients With New-Onset Heart Failure. American Journal of Cardiology, 2018, 121, 836-843.	0.7	4
603	Diuretics in cardiorenal syndrome: whatâ€™s new?. Intensive Care Medicine, 2018, 44, 359-362.	3.9	4
604	Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer. American Journal of Cardiology, 2020, 137, 118-124.	0.7	4
605	Evidence of Clonal Hematopoiesis and Risk of Heart Failure. Current Heart Failure Reports, 2020, 17, 271-276.	1.3	4
606	Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Cardiovascular Translational Research, 2020, 13, 519-527.	1.1	4
607	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 297-308.	0.7	4
608	Recent advances in the diagnosis and management of amyloid cardiomyopathy. Faculty Reviews, 2021, 10, 31.	1.7	4
609	Relation of Malnutrition to Outcome Following Orthotopic Heart Transplantation. American Journal of Cardiology, 2021, 142, 156-157.	0.7	4
610	Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside. Journal of Cardiac Failure, 2021, 27, 1053-1060.	0.7	4
611	Durable Mechanical Circulatory Support in Adult Congenital Heart Disease: Reviewing Clinical Considerations and Experience. Journal of Clinical Medicine, 2022, 11, 3200.	1.0	4
612	FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling. JCI Insight, 2022, 7, .	2.3	4

#	Article	IF	Citations
613	Exploring new drugs for heart failure: the case of urocortin. European Heart Journal, 2007, 28, 2561-2562.	1.0	3
614	Pharmacologic Therapy for Acute Heart Failure. Cardiology Clinics, 2007, 25, 539-551.	0.9	3
615	Collaboration Among General Cardiologists, Heart Failure Specialists, and Electrophysiologists: What Are the Barriers?. American Journal of Cardiology, 2007, 99, S41-S44.	0.7	3
616	Cellular Proliferative Response to Cardiac Troponinâ€Ł in Patients with Idiopathic Dilated Cardiomyopathy. Clinical and Translational Science, 2011, 4, 317-322.	1.5	3
617	Introduction. Progress in Cardiovascular Diseases, 2012, 55, 1-2.	1.6	3
618	Heart Failure Notwithstanding Ejection Fraction (HFnEF)â€"A Possible Unifying Hypothesis?. Journal of Cardiac Failure, 2014, 20, 60-62.	0.7	3
619	Worsening Heart Failure. JACC: Heart Failure, 2015, 3, 404-407.	1.9	3
620	Reply. Journal of the American College of Cardiology, 2016, 68, 2917-2918.	1.2	3
621	Carbamylated Low-Density Lipoprotein and Thrombotic Risk in ChronicÂKidneyÂDisease â^—. Journal of the American College of Cardiology, 2016, 68, 1677-1679.	1.2	3
622	I will take my heart failure â€˜lactateâ€freeâ€™ please. European Journal of Heart Failure, 2018, 20, 1019-1020.	2.9	3
623	Can Blood Volume Analysisâ€"Guided Acute Heart Failure Therapy ImproveÂClinical Outcomes?. JACC: Heart Failure, 2018, 6, 949-950.	1.9	3
624	Implications of Perceived Dyspnea and Global Well-Being Measured by Visual Assessment Scales During Treatment for Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 402-408.	0.7	3
625	Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 693-695.	2.9	3
626	Impact of timing of atrial fibrillation, CHA2DS2-VASc score and cancer therapeutics on mortality in oncology patients. Open Heart, 2020, 7, e001412.	0.9	3
627	Multimodal analgesia using opioid-sparing regimen in patients undergoing left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2020, 39, 977-979.	0.3	3
628	Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with betaâ€blockers. ESC Heart Failure, 2020, 7, 3049-3058.	1.4	3
629	Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS. Journal of the American Heart Association, 2020, 9, e016203.	1.6	3
630	Egg Consumption and Risk of Cardiovascular Disease: a Critical Review. Current Emergency and Hospital Medicine Reports, 2021, 9, 25-37.	0.6	3

#	ARTICLE	IF	CITATIONS
631	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart, 2021, , heartjnl-2020-318333.	1.2	3
632	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. American Heart Journal, 2021, 239, 110-119.	1.2	3
633	Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. Core Evidence, 2008, 3, 31-43.	4.7	3
634	Anemia in heart failure:current evidence and challenges. Reviews in Cardiovascular Medicine, 2007, 8, 78-86.	0.5	3
635	Usefulness of Serum Biomarkers of Endothelial Glycocalyx Damage in Prognosis of Decompensated Patients with Heart Failure with Reduced Ejection Fraction. American Journal of Cardiology, 2022, 176, 73-78.	0.7	3
636	Biomarkers of risk stratification in congestive heart failure: North American view. Biomarkers in Medicine, 2009, 3, 443-452.	0.6	2
637	Clinical Evaluation of Heart Failure. , 2011, , 511-525.		2
638	Ivabradine in Heart Failure: To SHIFT or Not to SHIFT. Current Heart Failure Reports, 2011, 8, 1-3.	1.3	2
639	Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated with Poor Long-Term Outcomes in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2014, 20, S40-S41.	0.7	2
640	Contribution of Environmental Toxins in the Pathogenesis of Idiopathic Cardiomyopathies. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 381.	0.4	2
641	Comparative Efficacy of Cardiac Resynchronization Therapy in Africans Americans Compared With European Americans. American Journal of Cardiology, 2015, 116, 1101-1105.	0.7	2
642	Alternative Biomarkers for Combined Biology. Heart Failure Clinics, 2017, 13, 381-401.	1.0	2
643	Reply. Journal of the American College of Cardiology, 2017, 70, 809.	1.2	2
644	Recent Advances in Understanding and Managing Cardiomyopathy. F1000Research, 2017, 6, 1659.	0.8	2
645	Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2018, 5, 180.	1.1	2
646	Intensive Blood Pressure Control and Body Size. Journal of the American College of Cardiology, 2018, 72, 1317-1318.	1.2	2
647	Following the Scent of Microbes Within: The Heart-Gut Connection. Journal of Cardiac Failure, 2019, 25, 328-329.	0.7	2
648	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 402-414.	0.7	2

#	Article	IF	Citations
649	Abstract 17746: Telecinobufagin, a Novel Cardiotonic Steroid, Promotes Myocardial and Renal Fibrosis via Na/K-ATPase Profibrotic Signalling Pathways. Circulation, 2014, 130, .	1.6	2
650	In heart failure, all beta-blockers are not necessarily equal.. Cleveland Clinic Journal of Medicine, 2003, 70, 1081-1087.	0.6	2
651	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	2
652	Phenomapping a Novel Classification System for Patients With Destination Therapy Left Ventricular Assist Devices. American Journal of Cardiology, 2021, , .	0.7	2
653	Targeting the Lymphatic System for Interstitial Decongestion. JACC Basic To Translational Science, 2021, 6, 882-884.	1.9	2
654	Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. JACC Basic To Translational Science, 2022, 7, 1-10.	1.9	2
655	Individual sentiments on telehealth in the COVID-19 era: Insights from Twitter. Progress in Cardiovascular Diseases, 2022, 71, 100-102.	1.6	2
656	Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation. Circulation: Cardiovascular Imaging, 2022, 15, e013829.	1.3	2
657	Supra-normal left ventricular ejection fraction in cardiac amyloidosis. Clinical Research in Cardiology, 2023, 112, 441-443.	1.5	2
658	Magnetic resonance imaging of cardiac metabolism in heart failure: how far have we come?. European Heart Journal Cardiovascular Imaging, 2022, 23, 1277-1289.	0.5	2
659	Is the tolerability of long-term thiazolidinedione therapy overstated? Reply. Journal of the American College of Cardiology, 2003, 42, 1334-1335.	1.2	1
660	Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. Current Cardiology Reports, 2004, 6, 200-204.	1.3	1
661	Does the underlying etiology influence plasma B-type natriuretic peptide levels of patients with isolated chronic aortic regurgiation and preserved left ventricular function?. Journal of Cardiac Failure, 2004, 10, S52.	0.7	1
662	Natriuretic Peptides in Screening for Cardiac Dysfunction. Heart Failure Clinics, 2006, 2, 323-332.	1.0	1
663	Natriuretic Peptides in Valvular Heart Diseases. Heart Failure Clinics, 2006, 2, 345-352.	1.0	1
664	Natriuretic Peptide Measurements in Managing Heart Failure. Circulation: Heart Failure, 2009, 2, 380-381.	1.6	1
665	Uncovering Interim Clinical Events at the Time of Clinical Encounter by Reviewing Intrathoracic Impedance Threshold Crossings. Journal of Cardiac Failure, 2011, 17, 893-898.	0.7	1
666	H2Sâ€"The Newest Gaseous Messenger on the Block. Journal of Cardiac Failure, 2012, 18, 597-599.	0.7	1

#	Article	IF	Citations
667	Cardiovascular Biomarker Assessment Across Glycemic Status. , 2015, , 245-268.		1
668	Prevention of Heart Failure in Patients with Chronic Kidney Disease. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	1
669	Can We Save the Kidneys by Protecting the Heart?. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 165-166.	2.2	1
670	Endothelinâ€1 is independently associated with 180â€day mortality after adjusting for body mass index. European Journal of Heart Failure, 2016, 18, 876-876.	2.9	1
671	Assessing Impedance in Heart Failure. Circulation: Heart Failure, 2016, 9, e002761.	1.6	1
672	Reconsidering Renal Sympathetic Denervation for Heart Failure. JACC Basic To Translational Science, 2017, 2, 282-284.	1.9	1
673	Hemodynamic Determinants of Right Heart Failure are Associated with Impaired T Cell Activation in Advanced Heart Failure. Journal of Cardiac Failure, 2019, 25, 774-775.	0.7	1
674	The New Promise of Mitochondrial Transplantation for Myocardial Recovery. JACC Basic To Translational Science, 2019, 4, 889-890.	1.9	1
675	Relationship Between the Transmural Dispersion of Repolarization and Volume Overload in Heart Failure. Journal of Cardiac Failure, 2020, 26, 93-94.	0.7	1
676	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007424.	1.6	1
677	New Advances and Ongoing Challenges in the Use of Biologic Agents in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	1
678	Impact of Cardiac Resynchronization Therapy on Global and Cardiac Metabolism and Cardiac Mitochondrial Function. Journal of Cardiac Failure, 2021, 27, 706-715.	0.7	1
679	Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. , 0, .		1
680	The role of cardiac imaging in hospitalized COVID-19â€“positive patients. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	1
681	Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis. Journal of Interdisciplinary Medicine, 2020, 5, 35-42.	0.1	1
682	Impact of body mass index on surgical coronary revascularization for ischaemic heart failure: insights from STICHES. ESC Heart Failure, 2020, 7, 4390-4393.	1.4	1
683	Contemporary Trends of Clinical Outcomes in Primary Left Ventricular Assist Device Implantation and Postprocedure High-Risk Categories. Journal of Cardiac Failure, 2022, 28, 270-282.	0.7	1
684	Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?. Current Heart Failure Reports, 2020, 17, 449-456.	1.3	1

#	Article	IF	Citations
685	Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. Frontiers in Physiology, 0, 13, .	1.3	1
686	Coronary revascularization for treatment of heart failure: optimal patient selection. ACC Current Journal Review, 2004, 13, 35-39.	0.1	0
687	Changing Conduction Abnormalities in a Dialysis Patient With Fever. Cardiology in Review, 2006, 14, 158-160.	0.6	0
688	Future Therapies in Diastolic Heart Failure. , 2008, , 435-441.		0
689	Biomarkers for Risk Stratification in Patients with Heart Failure. , 0, , 116-139.		0
690	Response to Letters Regarding Article, â€œTissue Doppler Imaging in the Estimation of Intracardiac Filling Pressure in Decompensated Patients With Advanced Systolic Heart Failureâ€• Circulation, 2009, 120, .	1.6	0
691	Enhancing the Prognostic Value of Cardiac Imaging With Multimodal Risk AssessmentâŽâŽEditorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.. JACC: Cardiovascular Imaging, 2009, 2, 1100-1102.	2.3	0
692	Targeting Endogenous Antioxidants to Prevent Cardiovascular Diseases. Journal of the American Heart Association, 2012, 1, e005215.	1.6	0
693	Reply. Journal of the American College of Cardiology, 2013, 61, 1659.	1.2	0
694	Cardiorenal Syndrome Revisited. , 2013, , 63-90.		0
695	Double-Chambered Right Ventricle and Bicuspid Pulmonic Valve. Journal of the American College of Cardiology, 2014, 63, 569.	1.2	0
696	Dexamethasone, Light Anaesthesia, and Tight Glucose Control (DeLiT) Randomized Controlled Trial. Survey of Anesthesiology, 2014, 58, 37-39.	0.1	0
697	Reply. Journal of the American College of Cardiology, 2015, 66, 2683-2684.	1.2	0
698	Heart Failure and Inflammatory Arthritis: the Relationship of Systemic Inflammation. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	0
699	Â¿CuÃ¡l debe ser el objetivo en la insuficiencia cardiaca: la hemoglobina o el hierro?. Revista Espanola De Cardiologia, 2016, 69, 811-812.	0.6	0
700	What Should We Target in Heart Failure: Hemoglobin or Iron?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 811-812.	0.4	0
701	Genetic Predispositions to Heart Failure. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	0
702	Novel Biomarkers of Heart Failure: Do They Have Incremental Clinical Utility?. Journal of Cardiac Failure, 2016, 22, 263-264.	0.7	0

#	Article	IF	Citations
703	Driving with the headlights on: Measuring adequate urinary sodium excretion on the road to precision diuresis. American Heart Journal, 2018, 203, 93-94.	1.2	0
704	Can saline repletion be the true TARGET for achieving fluid balance in acute heart failure?. European Journal of Heart Failure, 2019, 21, 1090-1092.	2.9	0
705	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0
706	A means to an end: the promise of tracking natriuresis with diuretic therapy. European Journal of Heart Failure, 2020, 22, 1448-1450.	2.9	0
707	Future Therapies in HFpEF. , 2021, , 489-494.		0
708	Identifying sodium <scp>nonâ€excretors</scp>: heart failure's emerging golden ticket for risk stratification. European Journal of Heart Failure, 2021, 23, 740-742.	2.9	0
709	Carbohydrate antigen 125 in heart failure: congestive kidneys or beyond?. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 484-486.	0.4	0
710	The Reply. American Journal of Medicine, 2021, 134, e466.	0.6	0
711	Modulating gut microbial metabolism in heart failure: Opportunities and challenges. EBioMedicine, 2021, 71, 103573.	2.7	0
712	The Reply. American Journal of Medicine, 2021, 134, e532.	0.6	0
713	Drugs Blocking the Renin-Angiotensin-Aldosterone System. , 2004, , 227-241.		0
714	New approaches to detect and manage edema and renal insufficiency in heart failure.. Cleveland Clinic Journal of Medicine, 2006, 73, S14-S14.	0.6	0
715	Telemonitoring and Sensor Technologies in Chronic Heart Failure. , 2013, , 205-237.		0
716	Abstract 19: Prognostic Value of Plasma Choline and Betaine Depend on the Intestinal Microflora-generated Metabolite Trimethylamine N-oxide. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
717	Targeting Oxidative Stress in Heart Failure. , 2014, , 993-1019.		0
718	Gut microbial function and bacterially derived signals in cardiovascular disease. Biochemist, 2017, 39, 22-25.	0.2	0
719	Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapy. , 2020, , 107-120.		0
720	In Reply: Familial hypercholesterolemia: Clarifications. Cleveland Clinic Journal of Medicine, 2020, 87, 320.2-320.	0.6	0

#	Article	IF	Citations
721	Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	0
722	Managing Cancer Patients and Survivors With Advanced Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	0
723	Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements. MedGenMed: Medscape General Medicine, 2006, 8, 62.	0.2	0
724	A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus. Vascular Health and Risk Management, 2007, 3, 639-45.	1.0	0
725	Case studies in advanced monitoring: OptiVol. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 1, S62-6.	0.5	0
726	Novel Therapies in Heart Failure. , 0, , 44-68.		0
727	Abstract 18178: Cardiotonic Steroid Lactone Ring Hydrolysis by Paraoxonases Attenuates Na/K ATPase Mediated Signaling. Circulation, 2015, 132, .	1.6	0
728	Abstract 21098: Variables From the CMS Heart Failure Readmission Model Poorly Predict 30-Day Rehospitalization Risk in Heart Failure Patients From a Large Academic Hospital System. Circulation, 2017, 136, .	1.6	0
729	Diagnostics and Prevention: Landscape for Technology Innovation in Precision Cardiovascular Medicine. , 2022, , 603-624.		0